Would be really interesting to see the co-mutational analysis of pts in the MORPHO trial, especially the genomics of those who relapsed on Gilteritinib, their relapse patterns and post-protocol therapy
Amer Zeidan MBBS,MHS عامر زيدان Naval Daver, M.D. Nico Gagelmann
#EHA2023 #EHA23 #leusm #bmtsm
#Amigotweetorials
Clinical VIGNETTE of the Week🥸
1/
55♂️
Presents with Tiredness🥱
Looking a pit pale 🎨
Blood film🔽
Representative Snapshots
#hemepath #MedTwitter #hemetwitter #leusm
An outstanding group of SCT Fellows, class of ‘23, at their graduation MD Anderson Cancer Center Curtis Marcoux Alejandro Marinos MD Konstantinos Lontos Dr. Elizabeth Shpall Richard Champlin Qaiser Bashir #bmtsm #mmsm #leusm #lymsm
#Amigotweetorials
An Amazing Slide for anyone Treating APL
When that next Pesky APL Variant Comes Knocking
Good to know what can work and what wont
🥸🥸
#medtwitter #hemepath #leusm
Attending on the UChicago Leukemia Program inpatient service for the next 14 days and will be sharing daily articles! #leusm #mpnsm #mdssm
Day 1 - Toyosi Odenike & my approach to accelerated/blast-phase MPNs
clinical-lymphoma-myeloma-leukemia.com/article/S2152-…
New interns are embarking on their postdoctoral training in teaching hospitals all around the world. Quote tweet or reply with your #TipsForNewDocs
I’ll start: Never worry alone! There’s always someone around whose job is to help you think through a tough case or situation.
Dasatinib 50 mg daily is as effective and less toxic than 100 mg daily for newly diagnosed CML-CP
Georgina Gener-Ricos Fadi Haddad, MD MD Anderson Cancer Center
Oncology Advance
authors.elsevier.com/c/1hE4t7fNb0A9…
#leusm #CML